We advocate this diagnostic approach not only in “triple negative” MPN patients (lacking driver mutations in JAK2, CALR or MPL as screened by the routine methods), but also in young individuals with MPN or unexplained polyglobulia or thrombocytosis, even in those with a low allele load of the known driver mutations. Here, MPL is linked to myeloproliferative neoplasm.